UNICA IRIS Institutional Research Information System

BARCELLONA, DORIS
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 123.830
NA - Nord America 7.951
AS - Asia 3.914
SA - Sud America 753
AF - Africa 180
OC - Oceania 61
Continente sconosciuto - Info sul continente non disponibili 5
Totale 136.694
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 121.685
US - Stati Uniti d'America 7.760
SG - Singapore 1.451
CN - Cina 1.089
BR - Brasile 574
SE - Svezia 469
VN - Vietnam 416
GB - Regno Unito 320
DE - Germania 305
UA - Ucraina 259
FI - Finlandia 197
HK - Hong Kong 183
FR - Francia 163
BD - Bangladesh 130
IN - India 124
CA - Canada 99
NL - Olanda 88
KR - Corea 64
AR - Argentina 61
MX - Messico 54
JP - Giappone 53
IQ - Iraq 52
TR - Turchia 51
AU - Australia 50
ZA - Sudafrica 49
AT - Austria 43
ES - Italia 43
IE - Irlanda 43
PK - Pakistan 38
PL - Polonia 37
IR - Iran 36
EG - Egitto 33
ID - Indonesia 33
MA - Marocco 31
CO - Colombia 30
RU - Federazione Russa 29
EC - Ecuador 24
MY - Malesia 21
UZ - Uzbekistan 21
BE - Belgio 20
DK - Danimarca 19
PH - Filippine 19
SA - Arabia Saudita 18
CH - Svizzera 17
TW - Taiwan 16
KE - Kenya 15
PY - Paraguay 15
CL - Cile 13
JO - Giordania 13
TN - Tunisia 13
ET - Etiopia 12
LT - Lituania 12
PE - Perù 12
CZ - Repubblica Ceca 11
NP - Nepal 11
NZ - Nuova Zelanda 11
BG - Bulgaria 10
VE - Venezuela 10
AE - Emirati Arabi Uniti 9
JM - Giamaica 9
HU - Ungheria 8
IL - Israele 8
SD - Sudan 8
DZ - Algeria 7
RO - Romania 7
TH - Thailandia 7
UY - Uruguay 6
BH - Bahrain 5
CR - Costa Rica 5
CY - Cipro 5
KZ - Kazakistan 5
NO - Norvegia 5
PT - Portogallo 5
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
BY - Bielorussia 4
GE - Georgia 4
GY - Guiana 4
KG - Kirghizistan 4
LB - Libano 4
LV - Lettonia 4
MU - Mauritius 4
OM - Oman 4
PA - Panama 4
PR - Porto Rico 4
EU - Europa 3
HN - Honduras 3
KW - Kuwait 3
LK - Sri Lanka 3
LU - Lussemburgo 3
MT - Malta 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
AL - Albania 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DM - Dominica 2
DO - Repubblica Dominicana 2
EE - Estonia 2
Totale 136.661
Salva come PNG Salva come JPEG
Città #
Cagliari 115.584
Uta 5.371
Fairfield 765
Ashburn 704
Singapore 677
Woodbridge 526
Dallas 506
San Jose 411
Houston 405
Boardman 316
Seattle 309
Nyköping 296
Chandler 293
Wilmington 287
Cambridge 261
Ann Arbor 246
Beijing 230
Council Bluffs 205
Hong Kong 158
Los Angeles 158
Helsinki 140
Jacksonville 134
Ho Chi Minh City 120
Santa Clara 120
The Dalles 120
New York 117
Shanghai 103
Lauterbourg 96
Dearborn 93
Boston 84
Hanoi 79
Rome 75
Buffalo 64
Dong Ket 58
San Diego 56
São Paulo 56
Milan 53
Nanjing 52
Munich 51
Hefei 48
Seoul 47
Chicago 43
Redwood City 42
Frankfurt am Main 39
Nuremberg 38
Redondo Beach 38
Guangzhou 37
Dublin 31
Tokyo 31
Toronto 30
London 28
Vienna 28
Warsaw 27
Johannesburg 25
Shenyang 25
Atlanta 23
Phoenix 23
Stockholm 23
Brandenburg 22
Orem 22
Amsterdam 21
Brooklyn 20
Tashkent 20
Tianjin 20
Denver 19
Sydney 19
Baghdad 18
Chennai 18
Hebei 18
Rio de Janeiro 18
Selargius 18
Ankara 17
Brussels 17
Haiphong 17
Mexico City 17
Turku 17
Bogotá 16
Changsha 16
College Station 16
Lahore 16
Nanchang 16
Manchester 15
Redmond 15
Central 14
Jiaxing 14
Nairobi 14
Salt Lake City 14
Sassari 14
Montreal 13
Mountain View 13
San Francisco 13
Amman 12
Mumbai 12
Orange 12
Baoding 11
Biên Hòa 11
Cape Town 11
Da Nang 11
Delhi 11
Istanbul 11
Totale 130.664
Salva come PNG Salva come JPEG
Nome #
Abnormal lipid accumulation and cluster formation of naive peripheral blood mononuclear cells: a useful tool for early detection of central nervous system damage in elderly 2.881
Heterogeneity of Antiphospholipid Syndrome (APS) as Characterized by Brain Perfusion Techniques. Towards New Ways of Syndrome Characterization 2.812
The venous thromboembolic risk and the clot wave analysis: a useful relationship? 2.772
Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review 2.756
Myocardial infarction and Antiphospholipid Syndrome: A first study on finger PPG waveforms effects 2.578
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. 2.572
Olanzapine-associated portal and superior mesenteric vein thrombosis 2.520
Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? 2.436
Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home 2.313
Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena 2.302
Empathy and the Educational Approach to Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants 2.184
Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al 2.169
Management of Patients Taking Oral Anticoagulants Who Need Urgent Surgery for Hip Fracture 2.155
Multiple specialized stem cell niches characterize hematopoiesis in the human fetal liver 2.085
Pulmonary Thrombosis: A Clinical Pathological Entity Distinct from Pulmonary Embolism? 2.078
Clot Waveform Analysis: From Hypercoagulability to Hypocoagulability - A Review 2.018
A Sardinian Family with Factor XI Deficiency 1.998
Ultrastructural findings of lung injury due to Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) following COVID-19 vaccination: a scanning electron microscopic study 1.967
Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: A report of an autoptic case and review of the literature 1.901
A “Catastrophic” Heparin-Induced Thrombocytopenia 1.890
The hemostatic system. 1st Part 1.814
Points of Care Testing International Normalized Ratio: Are They Useful for Monitoring Vitamin K Antagonists in a Thrombosis Center? 1.810
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.752
Point-of-care testing INR: an overview 1.682
Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No 1.663
Pulmonary thrombosis in 2019-nCoV pneumonia? 1.658
Risk of reoperation in bioprosthetic valve patients with indication for longterm anticoagulation. Results from the observational retrospective multicentre PLECTRUM study 1.650
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 1.627
Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants 1.605
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study 1.577
Direct oral anticoagulants: what can we learn? 1.569
Comparison of prothrombin time INR and clot waveform analysis performed with 129-mmol/L and 105-mmol/L citrate tubes 1.564
Fatal Cytopenia Induced by Low-Dose Methotrexate in Elderly With Rheumatoid Arthritis. Identification of Risk Factors 1.515
The criteria of the Italian Federation of Thrombosis Centres on DOACs: a ‘‘real world’’ application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist 1.485
Allele 4G of gene PAI-I associated with prothrombin mutation G20210A increases the risk for venous thrombosis 1.459
Thrombosis centres and AVKs monitoring in COVID-19 pandemic 1.446
Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients on oral anticoagulants 1.393
Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease? 1.368
Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills 1.352
A guide to oral anticoagulation 1.333
Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry 1.315
Portable coagulometer for vitamin K-antagonist monitoring: the patients’ point of view 1.307
The Repeatable Battery for the Assessment of Neuropsychological Status as a screening strategy for HIV-Associated Neurocognitive Disorders 1.304
Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided? 1.291
The Italian START-Register on anticoagulation with focus on atrial fibrillation 1.268
Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists 1.255
Heparins and 2019-nCoV infection: a narrative review 1.247
A ‘‘two-step’’ educational approach for patients taking oral anticoagulants does not improve therapy control 1.232
Thyroid disorders and hypocoagulability 1.186
The predictive ability of bleeding risk stratification models in very old patients on vitaminK antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 1.183
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome 1.153
High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice 1.133
Vitamin K antagonists (coumarins), drugs used in the prevention and treatment of cardioembolism, deep vein thrombosis, and pulmonary embolism 1.129
Liver changes in Wilson’s disease: The full spectrum. A report of 127 biopsies from 43 patients 1.106
Fetal programming of atherosclerosis: may the barker hypothesis explain the susceptibility of a subset of patients to develop stroke or cardiac infarct? 1.090
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 1.089
Association of Antiplatelet and Anticoagulant Treatment in Patients with Mechanical Prosthetic Heart Valves. Data from the Observational Multicentre PLECTRUM Study 1.081
A routine silica-based activated partial thromboplastin time (Hemosil aPTT-SP (TM)) mostly excludes the presence of lupus anticoagulant 1.078
Rheumatoid arthritis and thrombosis 1.078
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) 1.072
Fetal programming of COVID-19: May the barker hypothesis explain the susceptibility of a subset of young adults to develop severe disease? 1.016
Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful? 1.010
Infectious agents including COVID-19 and the involvement of blood coagulation and fibrinolysis. A narrative review 1.008
Clot characterization by multidisciplinary approach: biochemical and imaging parameters in a hypocoagulative setting. A pilot study 1.000
Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Società Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Società Italiana per lo Studio dell’Emostasi e della Trombosi (SISET) 938
Thrombotic sinusoiditis and local diffuse intrasinusoidal coagulation in the liver of subjects affected by COVID-19: The evidence from histology and scanning electron microscopy 906
Aortic vulnerability to COVID-19: Is the microvasculature of vasa vasorum a key factor? A case report and a review of the literature 898
Management of DOAC in patients undergoing planned surgery or invasive procedure: FCSA position paper 874
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 851
null 845
Managing anticoagulation in the COVID-19 era between lockdown and reopening phases 845
Scanning electron microscopy of lung disease due to COVID-19 – a case report and a review of the literature 843
Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk 832
Chronic spontaneous urticaria: a low-grade disseminated intravascular coagulation only partially reversed by Omalizumab 826
null 824
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 824
Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk 791
null 789
Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants 780
null 772
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET 744
Comparison of anticoagulation quality between acenocoumarol and warfarin in patients with mechanical prosthetic heart valves: Insights from the nationwide PLECTRUM study 743
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation 692
null 679
null 644
null 633
null 617
null 616
null 579
null 573
null 547
null 491
Over-anticoagulation by vitamin K antagonists and gender differences 480
Hormones and thrombosis: the dark side of the moon 459
Contraceptives and Thrombosis: An Intertwined Revolutionary Road 453
null 440
null 436
Performance and Interpretation of Clot Waveform Analysis 431
Why Does Rivaroxaban Not Work in Severe Mitral Stenosis? 417
Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? 409
Totale 129.861
Salva come PNG Salva come JPEG
Categoria #
all - tutte 183.131
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 183.131
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.240 0 0 0 0 0 0 0 0 0 0 0 1.240
2021/20228.985 796 650 357 537 721 713 592 531 736 1.001 1.211 1.140
2022/202313.417 1.236 1.862 1.850 1.246 1.120 1.337 652 821 814 790 1.040 649
2023/202413.891 477 803 541 950 1.432 2.101 2.368 987 653 891 1.330 1.358
2024/202530.870 6.693 8.203 5.303 2.881 2.608 1.761 2.023 130 332 427 212 297
2025/20268.219 491 285 1.012 704 625 497 1.329 520 684 1.166 655 251
Totale 137.216